Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMW8QNG)

Drug Name

Brolucizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Wet age-related macular degeneration	9B78.3Z	Approved	[1]
Diabetic macular edema	9B71.02	Phase 3	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN	Inhibitor	[3]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Vascular endothelial growth factor A (VEGFA)	DTT	VEGFA	8.544	6.927	7.253	7.839

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Wet age-related macular degeneration

ICD Disease Classification

9B78.3Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Vascular endothelial growth factor A (VEGFA)	DTT	VEGFA	3.61E-01	0.15	0.47

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	ClinicalTrials.gov (NCT04058067) To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (KINGLET). U.S. National Institutes of Health.
3	Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.